CHI is delighted to announce a new and improved Oligonucleotide & Precision Therapeutics (OPT) Congress for 2019. To complement our 4th annual Oligonucleotide Discovery and Delivery conference we are introducing a 2 day program
dedicated to Oligonucleotide CMC and Regulatory Strategies. In addition, we deliver two in-depth symposiums focusing on Drug Discovery for Rare Diseases and New Frontiers in Gene Editing and Repair.
Bringing together leading discovery scientists, developers, CMC experts, regulatory specialists and technology providers, OPT Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide therapies throughout
the drug development process. Attend in 2019 to optimize your drug design, delivery and performance, accelerate time to market and achieve commercial success.
Philip John (P.J.) Brooks, PhD, Program Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)
Richard S. Geary, PhD
Senior Vice President (SVP), Development, Ionis Pharmaceuticals
Muthiah (Mano) Manoharan, PhD
Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals
Ekkehard Leberer, PhD
Senior Director, R&D Alliance Management, Sanofi
David Horn Solomon, PhD, CEO, Silence Therapeutics
With thanks to our Executive Advisory Board
Arthur Levin, PhD
Executive Vice President, Research and Development, Avidity Biosciences
Muthiah (Mano) Manoharan, PhD
Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals
Lubo Nechev, PhD
Vice President Process and Analytical Sciences, Alnylam Pharmaceuticals
Dmitry Samarsky, PhD
CTO, Sirnaomics